See also the new 2007 Abstracts

Back to the NHL Cyberfamily Home Page

CONTENTS

1. B-Cell Lymphoma: Chemotherapy, excluding Pre-Clinical Models

2. Biology: Low Grade Lymphomas, including Waldenstroms

3. Clinical Results: Allogeneic Matched Related Donor Transplantation

4. Experimental Transplantation: Basic Biology, Immune Function, and Engraftment

5. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents

6. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models

7. Acute and Chronic GVHD

8. Biology: Aggressive Lymphomas, including Post-Transplant Lymphoproliferative Disorders (PTLD), Hodgkin and Mantle Cell Lymphoma

9. Clinical Results: Allogeneic Matched Related Donor Transplantation II

10. Clinical Results: Alternative Donor Transplantation – Cord Blood and Other

11. Clinical Results: Autologous Transplantation in Lymphoma

12. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents II 

13. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models II

14. T-Cell and Hodgkin Lymphoma: Chemotherapy, excluding Pre-Clinical Models

15. Transplantation Regimen Toxicities and Engraftment II

16. B-Cell Lymphoma: Clinical Chemotherapy Trials

17. Clinical Results: Allogeneic Matched Related Donor Transplantation –Non-Myeloablative Approaches

18. Experimental Transplantation: T-Cell Recovery and Immunotherapy

19. Acute and Chronic GVHD

20. BCL-6 and Gene Expression Profiling in NHL

21. Clinical Results: Allogeneic Matched Related Donor Transplantation – Myeloablative Approaches

22. Lymphoma: Novel Chemotherapy and Pediatric Clinical Trials

23. Clinical Results: Autologous Transplantation

24. Lymphoma: Chemotherapy, excluding Pre-Clinical Models

25. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models III

26. Transplantation Regimen Toxicities and Engraftment III

27. Lymphoma: Pre-Clinical – Immunotherapy

28. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models I

29. Transplantation Regimen Toxicities and Engraftment I

30. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models II

31. Reduced Intensity Transplantation: Clinical Outcome

32. Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

33. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models III

34. Transplantation Regimen Toxicities and Engraftment II

B-Cell Lymphoma: Chemotherapy, excluding Pre-Clinical Models

[920] Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

[921] Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia. The M.D. Anderson Cancer Center Experience.

[922] Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

[923] Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

[924] Intensive Chemotherapy (LMB-86 Regimen) for AIDS-Related Burkitt's Lymphoma/Leukemia.

[925] The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP).

[926] Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.

[927] The Stage-Modified IPI (MIPI), Histology and a Combined Treatment Influence the Clinical Outcome of 401 Patients with Primary Extranodal Head and Neck B-Cell Lymphomas (PHNBCL) (IELSG 23).

[928] Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.

[929] Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation.

[930] The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy.

[931] Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.

[932] Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

[933] Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL).

[934] A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

[935] Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymhoma (PMLBCL).

[936] Treatment of Post-Transplant Lymphoproliferative Disorder (PTLD) with Rituximab or Chemotherapy: The University of Pennsylvania Experience.

[937] Enhanced Safety and Tolerability of Dose Intensive Pentostatin and Rituximab in Patients with CLL or Low-Grade B-Cell NHL.

[938] Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

[939] Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell Lymphoma (DLBCL).

[940] Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma: Results of a Pilot Study.

[941] Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

[942] Clinical Features and Prognostic Factors in 135 NHL of the Head and Neck Treated by the GOELAMS 02 Trial.

[943] Phase II Study of Sphingosomal Vincristine in CHOP+/ - Rituximab for Patients with Aggressive Non-Hodgkin's Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.

[944] Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

[945] Results of a Pilot Trial of Fludarabine, Mitoxantrone and Rituxan in Mantle Cell Lymphoma.

Biology: Low Grade Lymphomas, including Waldenstroms

[977] Cloning of B Cell Lymphoma-Associated Antigens Using Modified Phage Displayed Expression cDNA Library and Immune Patient Sera.

[978] Ocular Adnexal Lymphoma: A Clinicopathological Study of a Large Cohort of Patients with No Evidence for an Association with Chlamydia psittaci.

[979] Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.

[980] Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.

[981] Survival Impact of Time Repeated bcl2/IgH Rearrangement Measurements in Follicular Lymphoma Patients Treated with Front-Line Autotransplantation in the GELF-94 Trial by the GELA.

[982] Strong BCL10 Nuclear Expression Identifies Gastric MALT Lymphomas That Do Not Respond to H. pylori Eradication.

[983] A Distinct Entity of Ocular Adnexal MALT Lymphoma with Trisomy 18.

[984] A Proteomic Approach to Discovery of Candidate Proteins Involved in the Transformation of Follicular Lymphoma.

[985] Bone Marrow BCL2/IgH+ Cells at Diagnosis and Not FCGRIIIA Polymorphism Predict Response in Follicular Non-Hodgkin's Lymphoma Patients Treated with Sequential CHOP and Rituximab.

[986] 6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.

[987] HCV Infection in Nongastric Marginal Zone B-Cell Lymphoma of MALT.

[988] SELDI-TOF Identifies Specific Protein Patterns in Small Lymphocytic Lymphoma, Marginal Zone Lymphoma and Mantle Cell Lymphoma.

[989] Combined Overexpression of Bcl-2 and SOCS3 Is Associated with Decreased Survival in a Cohort of Patients with De Novo Follicular Lymphoma.

[990] MUM1 Expression in Follicular Lymphoma Identifies a Group of Patients with Poor Overall Survival.

[991] Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom's Macroglobulinemia (WM).

[992] Reactive Oxygen Species (ROS) Are Induced by vFLIP and Regulate NF-kB Activation in KSHV-Infected Primary Effusion Lymphoma Cells.

[993] Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

[994] IgM-Expressing Waldenstrom's Macroglobulinemia Tumor Cells Reveal a Potential for Isotype Switch.

[995] Clonal Genetic Progression in t(14;18)-Positive Follicular Lymphomas.

[996] The Unfolded Protein Response Is a Determinant of Disease Actvity in Waldenstrom's Macroglobulinemia (WM).

[997] Mast Cells in the Diffuse Large B-Cell Lymphoma; Their Role for Fibrosis.

[998] Is There an Association between Ocular Adnexal Lymphoma and Chlamydia psittaci Infection? The University of Rochester Experience.

[999] No Association between Chlamydia Psittaci and Ocular Adnexal Lymphoma in North American Samples.

[1000] Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.

[1001] Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Is Associated with Unfavorable Prognostic Factors in Untreated Follicular Lymphoma.

[1002] Clonotypic IgG B Cells in Waldenstrom Macroglobulinemia Cells Are Derived from Multiple Post-Transformed B Cells That Have Undergone Isotype Switch Recombination.

[1003] Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom's Macroglobulinemia.

[1004] Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgVH) Somatic Hypermutation in Small B-Cell Lymphomas.

[1005] Molecular Analysis of the VH Gene Usage in a Familial Case of Waldenstrom's Macroglobulinemia.

[1006] Use of a Tissue Microarray To Assess the Accuracy of Lymphoma Classification by Needle Biopsy.

Clinical Results: Allogeneic Matched Related Donor Transplantation

[1125] Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

[1126] Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

[1127] Clinical Outcome of Stem Cell Transplantation(SCT) in Patients with T Cell Prolymphocytic Leukaemia(T-PLL) Previously Treated with Alemtuzumab: A Multicentre Experience.

[1128] Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL).

[1129] Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

[1130] Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

[1131] Ibritumomab Tiuxetan (Zevalin) in the Conditioning Regimen for Autologous and Reduced-Intensity Allogeneic Stem-Cell Transplantation in Patients with Chemo-Refractory Non-Hodgkin's Lymphoma.

[1132] Non-Myeloablative vs. Conventional Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma.

[1133] Prolonged Remissions with Autologous and Allogeneic Stem Cell Transplantation for Burkitt's Lymphoma: Long Term Follow-Up at a Single Institution.

[1134] Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

[1135] Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

[1136] Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) May Have a Benefit in Acute Lymphoblastic Leukemia (ALL) Outcome.

[1137] HLA Identical Hematopoietic Stem Cell Transplantation for Acute Leukemia in Children – A Single Center Experience.

[1138] Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).

[1139] Comparative Outcome of Reduced Intensity and Myeloablative Preparative Regimen in HLA Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years of Age with Acute Myeloblastic Leukaemia: A Retrospective Survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT).

[1140] Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

[1141] Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning (RIC) Regimen Has the Capacity To Produce Durable Remissions and Long Term Disease-Free Survival in Patients with High Risk Acute Myeloid Leukemia (AML).

[1142] Allogeneic Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies Not in Remission: The Anti-Tumor Effect of Reduced-Intensity Conditioning Is Comparable to That of Conventional Myeloablative Conditioning.

[1143] Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

[1144] Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.

[1145] Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics.

[1146] Impact of Hematopoietic Stem Cell (HSC) Recruitment and Graft Composition on Transplant Outcome after Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Study of the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.

[1147] Prognostic Factors for Outcome of Patients Undergoing Allogeneic HSCT from Unrelated and Related Donors for AML and MDS: A Retrospective Analysis. Session Type: Poster Session 305-I - 09:15 AM - Hall B4

Experimental Transplantation: Basic Biology, Immune Function, and Engraftment

[1257] IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.

[1258] Effective Depletion of Alloreactive T Cells by CD95l-Transduced Cells with Preservation of FoxP3 Regulatory T-Cells.

[1259] Defective Engraftment of HSPC from C3aR-/- Mice Reveals an Underappreciated Role of C3a-C3aR Axis in Stem Cell Homing to Bone Marrow.

[1260] Evidence for Involvement of Clonally Expanded CD8+ T Cells in Anti-Cancer Immune Responses in CLL Patients Following Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT).

[1261] Long-Term Engraftment and Self-Renewal of AML Stem Cells in the Newborn NOD-scid/IL2rgnull Immunodeficient Mouse Model.

[1262] Signaling Profiles of T Cells during Allogeneic Hematopoietic Stem Cell Transplantation.

[1263] Isolation and Characterization of Human CD4+CD25+ T Regulatory Cells for Early Phase Clinical Trials in Hematopoietic Cell Transplantation.

[1264] Higher Homeostatic Set-Point for Transplanted Naive vs. Memory CD8 T Cells during Immune Reconstitution Following Ablative Conditioning and HCT.

[1265] Characterization of an Immunodeficient Mucopolysaccharidosis Type I (MPS-I) Mouse Model Suitable for Preclinical Testing of Human Stem Cell and Gene Therapy.

[1266] Transfusion of Leukoreduced RBC Results in Immunization to Minor Histocompatibility Antigens by Crosspriming into Recipient MHC Class I Pathways.

[1267] Mesenchymal Stem Cells Promote the Engraftment of Cord Blood CD34+ Cells but Do Not Accelarate Platelet Recovery NOD/SCID Mice

[1268] Antigen-Specific CD8+ Memory T Cells Survive, Function and Populate the Host Marrow Compartment Following Ablative TBI and Allogeneic BMT.

[1269] Lack of Immune Barrier to Allogeneic Hematopoietic Stem Cell Engraftment in T, B, and NK Cell Deficient (Rag2γc-/-) Mice.

[1270] Improved Analysis of Hematopoietic Engraftment by Non-Invasive In Vivo Bioluminescent Imaging of Transplanted Human Embryonic Stem Cell-Derived Hematopoietic Cells.

[1271] Androgen Modulates Thymopoiesis by Regulating Thymocyte Precursor Immigration.

[1272] PBSC Mobilization by the Chemokine GROβ Alone and in Combination with G-CSF in Mice Demonstrates the Same Inter-Strain Variability in Mobilization Response as G-CSF and Is Dependent upon Differences in Neutrophil Pro-MMP-9 Content and Release.

[1273] CD154:CD40 Co-Stimulatory Blockade: A Novel Approach To Prevent Sensitization to Donor Alloantigens.

[1274] Tracking Differential Repopulation Kinetics of Human Hematopoietic Progenitor Cells Using MRI Detection of Nanoparticles.

[1275] CD26 Inhibition Enhances Allogeneic Donor Cell Homing and Engraftment after In Utero Bone Marrow Transplantation.

[1276] Enhanced In Vivo Homing of Uncultured and Selectively Amplified Umbilical Cord Blood CD34+ Cells by Co-Transplantation with Cord Blood Derived Unrestricted Somatic Stem Cells.

[1277] Immunoregulatory Effects of Allogeneic Mixed Chimerism Induced by T-Cell Depleted, Nonmyeloablative Bone Marrow Transplantation on Chronic Inflammatory Arthritis and Autoimmunity Developed in Interleukin-1 Receptor Antagonist-Deficient Mice.

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents

[1469] Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.

[1470] A Humanized Anti-CD30 Monoclonal Antibody, XmAbTM2513, with Enhanced In Vitro Potency Against CD30-Positive Lymphomas Mediated by High Affinity Fc-Receptor Binding.

[1471] Preclinical Pharmacology and Toxicology of Humanized Anti-B-Cell Antibodies (Anti-CD22 and Anti-CD20) in Cynomolgus Monkeys (CM).

[1472] CHIR-12.12, an Antagonist Anti-CD40 Antibody, Exhibits Greater ADCC Than Rituximab Against a Variety of Malignant B Cells: Evaluation of FcγRIIIa Polymorphism and ADCC Response.

[1473] Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin's Lymphoma (NHL) Pre-Clinical Models.

[1474] Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL).

[1475] In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin's Lymphoma Cells (NHL).

[1476] The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin's Disease Cells through Multiple Mechanisms.

[1477] Anti-Tumor Effect of Direct Intratumor Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand in B Cell Lymphoma Model.

[1478] Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies.

[1479] Comprehensive Analysis of MHC Class I Peptides Presented on Adult T Cell Leukemia Cells by Mass-Spectrometry.

[1480] Successful In Vitro Priming of EBV-Specific CD8+ T Cells Endowed with Strong Cytotoxic Function for Prophylaxis or Treatment of PTLD in EBV Seronegative Hosts.

[1481] Improvement of Idiotype Vaccine Efficacy Using a Sulfhydryl-Based Carrier Protein Conjugation Method: Results in Multiple Murine Lymphoma Models.

[1482] In Vitro Expansion of Autologous Follicular Lymphoma-Specific T Cells for Adoptive Transfer.

[1483] The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.

[1484] BCL6, p53 and Molecular Targeted Therapy in B-Cell Lymphomas.

[1485] Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance.

[1486] Targeting Lymphoid Malignancies with Small Molecule Inhibitors of Pro-Survival Bcl-2 Proteins.

[1487] Sodium Orthovanadate (NaV) Effects CD22 Expression, Intracellular Signaling, and Lymphomacidal Activity of the HB22.7 Anti-CD22 Monoclonal Antibody.

[1488] Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines.

[1489] Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

[1490] The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models

[1491] Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases – Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.

[1492] Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.

[1493] A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

[1494] Efficient Vaccination of Follicular Lymphoma (FL) Patients with Multiple Intradermal (ID) and Intravenous (IV) Administrations of Mature Dendritic Cells (DC) Loaded with Tumor Cell Lysate Ex Vivo.

[1495] Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.

[1496] High-Grade Primary Gastric Lymphoma: A Retrospective Review of Clinicopathologic Features and Prognostic Factor Analysis in 214 Patients with High-Grade Gastric Lymphoma.

[1497] Adenovirus-Interferon-g (TG1042) Demonstates Clinical Activity in Relapsing Primary Cutaneous Lymphoma (PCL): A Phase I/II Multicentric Trial.

[1498] Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma.

[1499] Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

[1500] B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.

[1501] CD30 as Target for Radioimmunotherapy (RIT) of Lymphoma.

[1502] Lyposomal Doxorubicin (Caelyx), Cyclophosphamide – Rituximab (DC-R) Plus GM-CSF as a Salvage Therapy in B-Diffuse Large Cell Lymphoma (B-DLCL) after Autologous Stem Cell Transplantation (ASCT) Failure.

[1503] Rituximab in Relapsed Lymphocyte Predominant Hodgkin's Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

[1504] A Phase I Study of Humanized Anti-CD40 Immunotherapy with SGN-40 in Non-Hodgkin's Lymphoma.

[1505] Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide – Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

[1506] Treatment of High Risk Diffuse Large B-Cell Lymphomas (DLBCL) with Ntensive Induction Chemotherapy, Rituximab and Autologous Stem Cell Transplant.

[1507] Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases.

[1508] Rituximab during Pregnancy: Serum Levels, B Cell Counts and Immunoglobulin Levels in Mother and Child.

[1509] The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Related Non-Hodgkin Lymphoma: An Update of a Multicenter Study.

[1510] Anti-Interleukin 6 Receptor Monoclonal Antibody Therapy Reduced Serum Interleukin 4 and IgE Production in Castleman's Disease.

Acute and Chronic GVHD

[1797] Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.

[1798] Tacrolimus/Methotrexate (MTX) Versus Cyclosprorine/MTX for Graft-Versus-Host Disease (GVHD) Prophylaxis in Patients with Severe Aplastic Anemia (SAA) Who Received Marrow Transplantation from Unrelated Donors: Results of a Matched Pair Analysis.

[1799] Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

[1800] A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.

[1801] High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-?) and Interleukin-2 (IL-2) Blockade.

[1802] Low-Dose Methotrexate as Salvage Therapy for Refractory Graft-Versus-Host Disease (GVHD) after Reduced-Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (allo-SCT). 

[1804] Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients. 

[1805] Pentostatin in Steroid-Refractory Chronic Graft-Versus-Host Disease. 

[1806] Efficacy of Soluble TNF? Inhibitor (Etanercept) for Treatment of Steroid Refractory Acute Graft Versus Host Disease (GVHD) Post Allogeneic Stem Cell Transplantation (SCT). 

[1808] Chronic Graft-Versus-Host Disease after Allogenaic Bone Marrow Transplantation in Japan: Identification of Risk Factors and Prognostication. 

[1809] Clinical Outcomes and the Impact of Anti-Thymocyte Globulin (ATG) and Chronic Graft Versus Host Disease (cGVHD) Following Pediatric Allogeneic Stem Cell Transplantation: A Comparison between Peripheral Blood and Bone Marrow as a Source of Stem Cells. 

[1810] Inflammatory Cytokines and Acute Graft-Versus-Host Disease (aGVHD) after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).

[1811] CD1a Is a Dimorphic Antigen-Presenting Protein That May Be Mismatched without Increasing the Risk of Graft Versus Host Disease. 

[1812] Iron Overload Strongly Correlates with Acute Graft-Versus-Host-Disease of the Liver and Treatment Related Mortality after Allogeneic Hematopoetic Cell Transplantation (HCT).

[1814] Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB). 

[1815] Potential Involvement of Chemokine Fractalkine/CX3CL1 and CX3CR1high Monocytes in Chronic Graft Versus Host Disease. 

[1816] Interleukin-2-Producing CD4+OX40+ T Cell as a Target for the Treatment of Chronic Graft-Versus-Host-Disease. 

[1817] Outcome of Patients Developing GVHD after DLI for CML Relapse from HLA-Identical Sibling or VUD HSCT. 

[1818] Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation. 

[1819] Chronic Cutaneous GVHD Does Not Correlate with Frequency and FoxP3 Gene Expression of Regulatory T Cells. 

[1820] Relationship of Harvest CD34+ and CD3+ Counts To Chronic Graft-Versus-Host Disease (cGVHD), Relapse and Survival Following Sibling Allogeneic Stem Cell Transplant. 

[1821] Pulmonary Complications after T-Cell Depleted Allogeneic Stem Cell Transplantation: Low Incidence and Strong Association with Acute GVHD.

[1822] Home Telemetric System for Pulmonary Function Surveillance: A Useful Procedure for Detection of Late-Onset Noninfectious Pulmonary Complications (LONIPC) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). 

[1823] Pharmacokinetics (PK) of Mycophenolate Mofetil (MMF) in Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Are Associated with Significantly Higher Clearance.

Biology: Aggressive Lymphomas, including Post-Transplant Lymphoproliferative Disorders (PTLD), Hodgkin and Mantle Cell Lymphoma

[1904] Rescue of Germinal Centre B Cells with Inactivated Immunoglobulin Genes by EBV In Vitro Suggests a Common Mechanism in the Pathogenesis of Post-Transplant Lymphoproliferative Disease and Hodgkin's Disease.

[1905] In Pediatric Mature B-Cell Non Hodgkin Lymphoma (NHL), Complex Karyotype or del(13q) Are Linked Prognostic Factors in Burkitt Lymphoma (BL) While 8q24/c-myc Rearrangement Is Associated with a Strong Adverse Effect in Diffuse Large B-Cell Lymphoma (DLBCL).

[1906] Histology of Lymphomas with t(3;14)(q27;q32) Correlates with the Molecular Anatomy of the Translocation.

[1907] Development of B Cell Lymphoma in E?-Cyclin D1 X Mutant p53 Transgenic Mice.

[1908] Constitutive Activation of AKT Contributes to the Pathogenesis and Survival of Blastoid Variants of Mantle Cell Lymphoma.

[1909] RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.

[1910] Mantle Cell Lymphoma: Prognostic Capacity of the Follicular Lymphoma International Prognostic Index.

[1911] Conditional Survival of Patients with Diffuse Large B-Cell Lymphoma.

[1912] Molecular and Clinical Features of Diffuse Large B-Cell Lymphoma with MYC Alterations: Inverse Correlation with p53 Pathway Disruption.

[1913] All IPI Factors Are Equal, but LDH Is More Equal Than Others. Session Type:

[1914] Early Response Evaluation with 18FDG-PET Scanning, but Not Phenotypic Profile, Are Predictive of Outcome in Diffuse Large B-Cell Lymphoma.

[1915] Analysis of EBV-Specific T Cell Responses in Transplant Recipients with PTLD.

[1916] Molecular Analysis of Posttransplant Lymphoproliferative Disorders (PTLD) of Donor Origin Occuring in Liver Transplant Patients.

[1917] GCET2, a New Adaptor Protein in B Cell Signaling.

[1918] A Highly Effective Model of Risk Assessment in Diffuse Large B Cell Lymphoma (DLBCL) Using Classification and Regression Tree (CART) Analysis.

[1919] C-myc Abnormalities in Non-Hodgkins Lymphoma – A Retrospective Review of Cytogenetic Patterns and Clinical Impact of c-myc Abnormalities by FISH Testing.

[1920] P53 and p21waf1 Expression by Immunohistochemistry in Diffuse Large B-Cell Lymphoma Has a Strong and Independent Impact on Survival of Patients with Germinal Center Phenotype.

[1921] Clinical Features and Outcome of 147 Patients with Diffuse Large B-Cell Lymphoma and Hepatitis C Virus Infection.

[1922] Lack of BIC and microRNA miR-155 Expression in Primary Cases of Burkitt Lymphoma.

[1923] Interluekin-10 (IL-10) Promoter Gene Polymorphism (-819*C) Associated with Poor Clinical Outcome in DLBCL Patients Treated with R (Rituximab)-CHOP Regimen as a First Line.

[1924] CD19-Negative Diffuse Large B-Cell Lymphoma Shows High Serum LDH Level and Poor Prognosis.

[1925] MRD Detection in Mantle Cell Lymphoma: Flow Cytometry Is Comparable to Consensus Primer IgH-PCR at Initial Staging, but Less Sensitive Than PCR after Combined Immuno-Chemotherapy.

[1926] Serum BLyS Level as a Prognostic Marker in Patients with Lymphoma.

[1927] FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

[1928] Complete Loss or Severely Compromised Expression of the Pro-Apoptotic Protein Bax Leads to Resistance to Curcumin-Induced Apoptosis in Burkitt's Lymphoma Cells.

[1929] Posttransplant Lymphoproliferative Disorders in Pediatric Solid Organ Recipients: A Multicenter Retrospective Analysis of Patients from 1990 to 2003.

[1930] Stromal Incorporation of VEGFR-1+, CD68+ and ?-SMA+ Hemangiogenic Cells Correlates with Histologic Subtype in Non-Hodgkin's Lymphoma.

[1931] A Mid-Treatment FDG-Positron Emission Tomography (PET) Scan Is Highly Predictive of Subsequent Treatment Failure in Patients with Diffuse Large B-Cell Lymphoma (DLBCL).

[1932] Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin's Disease (HD); the Stanford V + Radiotherapy (RT) Experience.

[1933] Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays.

Clinical Results: Allogeneic Matched Related Donor Transplantation II

[2027] Outcome of Allogeneic Stem Cell Transplantation for Patients with Severe Aplastic Anemia after Conditioning with Procarbazine, ATG and Cyclophosphamide: A Single Center Experience. 

[2028] Fludarabine-Based HLA-Identical Sibling HSCT for Patients with Severe Aplastic Anemia (SAA) Older Than 30 Years: A Study from the French (SFGM-TC) and Italian (GITMO) Registries. 

[2029] Fludarabine Based Conditioning for Allogeneic Transplantation in Severe Aplastic Anemia. Session Type: Poster 

[2030] Matched Related Donor Transplants for Sickle Cell Disease: Report from the Center for International Blood and Transplant Research. 

[2031] Long-Term Outcome after Bone Marrow Transplantation for Adult Thalassemia. 

[2032] High Dose Busulfan and Fludarabine with Anti-Thymocyte Globulin (ATG) Followed by Unmodified Marrow Grafts from HLA-Matched Siblings for the Treatment of High Risk Hemoglobinopathies (HGBpathies). 

[2033] A Phase 3, Randomized, Placebo-Controlled Trial of Filgrastim in Patients (Pts) with Hematologic Malignancies (HM) Treated with a Myeloablative Conditioning Regimen and Allogenic Bone Marrow Transplantation (allo BMT). 

[2034] Birth Order and Outcome in HLA-Identical Sibling Donor Hematopoietic Stem Cell Transplants. Impact of a Sequential Fetomaternal – Maternofetal Cell Transfer? 

[2035] Directed Donor Cord Blood Transplantation for Hematological Disorders. 

[2036] Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors. 

[2037] Detectable Minimal Residual Disease before Haematopoietic Stem Cell Transplantation Predicts Extremely Poor Prognosis in Children with Acute Lymphoblastic Leukaemia. 

[2039] 5´-ABL Gene Deletion on Derivative Chromosome 9 Detected by FISH: Prognostic Significance in CML Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). 

Clinical Results: Alternative Donor Transplantation – Cord Blood and Other

[2040] Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation. 

[2041] Negative Impact of KIR-Ligand Mismatch on Transplant-Related Mortality (TRM) in Umbilical Cord Blood Transplant (UCBT) Recipients. 

[2042] A Single Center Experience with Allogeneic Sibling Umbilical-Cord-Blood Transplantation in Children with Malignant and Non-Malignant Disease. 

[2044] Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience. 

[2045] Clinical Outcome of Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells Prior to Cryopreservation. 

[2046] Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report. 

[2047] An Empirical Analysis of the Probability of Finding a Well Matched Cord Blood Unit: Implications for a National Cord Blood Inventory. 

[2048] Excellent Disease-Free Survival after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Only Conditioning Regimen in a Diverse Adult Population. 

[2049] Successful Umbilical Cord Blood Transplants in Adults Who Received a Nucleated Cell Dose ? 1 X 107 Cells/kg Processed by a Post-Thaw Non-Wash Procedure. 

[2050] Transplant Outcomes and Stabilization of Neurological Function in Young Children with MPS III (Sanfilippo Syndrome) after Unrelated Donor Umbilical Cord Blood Transplantation. 

[2051] Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality. 

[2052] Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors. 

[2056] Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor. 

[2057] Interleukin-1 ? Genotype and Outcome of Unrelated Donor BMT for CML. 

[2058] Monitoring Graft Function after First Allogeneic Transplant for Mucopolysaccharidosis-IH: Patterns of Rejection and Outcome of Second Allograft Procedure. 

[2059] Unrelated Bone Marrow Transplantation for Adult T Cell Leukemia/Lymphoma: A Study from the Japan Marrow Donor Program. 

[2060] Impact of HLA Class I Typing-Resolution and Mismatches on Survival and Graft-Versus-Host Disease in Patients after Hematopoietic Stem Cell Transplantations from Unrelated Donors.

[2061] Single Antigen Mismatched Related Donor Allogeneic Stem Transplants Have Similar Outcomes as Matched Unrelated Donor Allogeneic Stem Cell Transplants: A Single Center's Experience. 

[2062] Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life. 

[2063] Matched Related vs Alternative Donor Stem Cell Tranplantation (SCT) for Diamond Blackfan Anemia: A Report from the Diamond Blackfan Anemia Registry. 

[2066] Similar Survival after Bone Marrow Versus Peripheral Blood Stem Cell Transplantation from Matched Unrelated Donors in Children with Hematologic Malignancies. 

[2067] Is Antilymphocyte Globulin Useful in Conditioning Regimen of Unrelated Donor Hematopoïetic Stem Cell Transplantation? 

Clinical Results: Autologous Transplantation in Lymphoma

[2068] High CR Rate and Prolonged EFS in aaIPI 2 - 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

[2069] Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.

[2070] Upfront Autologous Stem Cell Transplantation (SCT) Ameliorates the Prognostic Disadvantage of an Intermediate/High-Risk FLIPI Score in Patients with Advanced Follicular Lymphoma (FL): Evidence from Two Independent Data Sets.

[2071] Final Report on Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin Lymphoma – A Two Institution Study.

[2072] The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).

[2073] High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin's Lymphoma.

[2074] Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-Cell Lymphomas. A Prospective Multicenter Study.

[2075] Benefit of the Adjunction of Rituximab in Salvage Regimen before Autologous Stem-Cell Transplantation (ASCT) in Follicular Lymphoma at Relapse. A Single Institution Study.

[2076] Frontline High-Dose Therapy (HDT) for Adults with Disseminated Aggressive Lymphoma (NHL): Analysis of 327 Patients Included in 3 Prospective Trials (GOELAMS 071, 072, 074) over 12 Years.

[2077] Intensive Chemotherapy (High-Dose CHOP/ESHAP Regimen) Followed by Autologous Stem-Cell Transplantation (ASCT) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL). Results of a Prospective Phase II Study from the GELCAB.

[2078] Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study.

[2079] BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma and Hodgkin's Disease: A Single Center Comparative Study of 219 Patients.

[2080] Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin's Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

[2081] Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma.

[2082] Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.

[2083] Autologous Stem Cell Transplantation (ABMT) for Recurrent Hodgkin's Disease from 1990-2005: Factors Contributing to Post-Transplant Relapse.

[2084] The Addition of Rituximab to High Dose Sequential Chemotherapy (HDS) Programs with Autologous Transplantation Significantly Improves the Outcome of Patients with Refractory or Relapsed B-Cell Non Hogkin's Lymphoma.

[2085] Outcomes of Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B Cell Lymphoma (PMLCL) Are Inferior to Diffuse Large B Cell Lymphoma (DLBCL).

[2086] Comparison of Outcomes in Elderly Patients with Non-Hodgkins Lymphoma Undergoing High-Dose Chemotherapy to Their Younger Counterparts: Greater Morbidity but No Significant Impact on Overall Survival.

[2087] Cyclosporine, Interferon-?, and Interleukin-2 Immunotherapy Is Tolerable and Induces Autoreactivity in Patients with Recurrent/Refractory Hodgkin Disease Undergoing Autologous Stem Cell Transplantation with BEAM: A COG Study.

[2088] High Dose Therapy (HDCT) and Autologous Haematopoietic Stem Cell Transplantation (aSCT) in Paediatric Patients with Recurrent or Refractory Hodgkin's Disease (HD): Results and Outcome.

[2089] Favorable Influence of Pretransplant Rituximab but Not of High-Dose Ara-C in Upfront Autologous Stem Cell Transplantation (SCT) for Mantle Cell Lymphoma (MCL).

[2090] Prognostic Value of FDG-PET in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

[2091] Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin's Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

[2092] Autologous Stem Cell Transplantation and Rituximab for Mantle Cell Lymphoma.

[2093] Allogeneic or Autologous Stem Cell Transplantation (SCT) for the Treatment of Pediatric Patients with Non-Hodgkins Lymphoma (NHL).

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents II 

[2406] Active Combination Therapy of Bortezomib (Velcade) and Ibritumomab Tiuxetan (Zevalin) in an In Vivo Diffuse Large B-Cell Lymphoma Model. 

[2407] Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma. 

[2408] Bortezomib (Velcade™) and the Bcl-2 Inhibitor HA14-1 Synergistically Stimulate Apoptosis in EBV-Transformed Lymphocytes: A Potential Approach to Treatment of EBV-Associated Lymphoproliferative Disorders. 

[2409] Inhibition of Proteasome Is Associated with Early Alterations of Cell Cycle Regulators and Induces Synergistic Antitumour Activities in Mantle Cell Lymphoma in a Sequence Dependent Manner. 

[2410] Cell Based Assays Completed with the Mantle Cell Lymphoma Cell Lines Z138 and NCEB-1 Indicate That Combinations of Bortezomid and Flavopiridol Interact To Achieve Synergistic Activity. 

[2411] Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines. 

[2412] Gene Expression Analysis Uncovers Possible Resistance Mechanisms to Bortezomib in Mantle Cell Lymphoma That Differ from Mechanisms Identified in Other Lymphoid Malignancies. 

[2413] Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD). 

[2414] Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

[2415] Inhibition of AKT/mTOR Signaling Induces Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma. 

[2416] Inhibition of Protein Kinase C beta by Enzastaurin (LY 317615) Induces Alterations of Key Regulators of Cell Cycle and Apoptosis in Mantle Cell Lymphoma and Synergizes with Chemotherapeutic Agents in a Sequence Dependent Manner. 

[2417] Treatment with Intermediate Subviral Particles Overcomes Resistance to Reovirus Induced Oncolysis in Mantle Cell Lymphoma Cell Lines. 

[2418] Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells. 

[2419] Activation of mTOR Signaling Pathway Contributes to Tumoral Cell Survival in ALK-Positive Anaplastic Large Cell Lymphoma. 

[2420] Targeting Antiapoptotic Bcl-2 Family Members with AT-101 in Pre-Clinical Models of Aggressive Lymphoma in Combination with Cyclophosphamide (C) and Rituximab (R) Produces a Marked Improvement in Therapeutic Efficacy. 

[2421] Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma. 

[2422] Heat Shock Protein 90 (HSP90) Is Overexpressed in Primary and Cultured Hodgkin Lymphoma (HL) Cells: Role of Therapeutic Targeting Using the Small Molecule Inhibitor 17-AAG. 

[2423] Preclinical Anti-Tumor Efficacy of ABT-510 (Thrombospondin-1 Mimetic Peptide), a Novel Anti-Angiogenic Agent, in Hematological Malignancies. 

[2424] Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (Velcade®) in Mantle Cell Lymphoma. 

[2425] The Novel Triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) Induces Apoptosis of Human Diffuse Large B-Cell Lymphoma Cells (DLCL) through a Peroxisome Proliferator-Activated Receptor ? (PPAR?) Independent Pathway Which Is Enhanced by NF?B Inhibition. 

[2426] The Triterpenoids 2-cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) and Their Imidazole (CDDO-Im) and Dinitrile Derivatives (DI-CDDO) Elicit Apoptosis through a Novel Mitochondrial Pathway. 

[2427] Oral Administration of the Opium Alkaloid Noscapine (NOS) Exhibits Potent Anti-Tumor Activity Against Non-Hodgkin's Lymphomas and Myeloma Cell Lines In Vitro and In Vivo in SCID-beige Murine Xenograft Models. 

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models II

[2428] Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin's Lymphoma.

[2429] Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.

[2430] Genetic Polymorphism of the Inhibitory IgG Fc Receptor Fc?RIIb Is Not Associated with Clinical Outcome of Rituximab Treated Follicular Lymphoma Patients.

[2431] Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin's Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

[2432] Rituximab Activity Is Potentiated by GM-CSF in Patients with Relapsed, Follicular Lymphoma: Results of a Phase II Study.

[2433] Polymorphisms in Fc?RIIIA Are Genetically Linked to Fc?RIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in Fc?RIIIA-158 in Determining Rituximab Responses.

[2434] CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

[2435] Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

[2436] Cost-Effectiveness of 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) Versus Rituximab Monotherapy in Patients with Relapsed Follicular Lymphoma.

[2437] A Phase I Study of Immunization of Indolent Non Hodgkin's Lymphoma Patients with Autologous Monocyte-Derived Dendritic Cells Loaded with Heat Shocked and Killed Autologous Tumor Cells. Session Type: Poster

[2438] Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax® Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin's Lymphoma (NHL).

[2439] ?? T Cell-Mediated Immunotherapy of Malignancies with Zoledronate and IL-2.

[2440] Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Interleukin-15 or CpG Oligodeoxynucleotides.

[2441] BiovaxID™ Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial and Status of a Controlled, Randomized Phase III Trial.

[2442] Thalidomide in Combination with Rituximab Is Active in Waldenström's Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

[2443] Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström's Macroglobulinemia: Preliminary Safety and Efficacy Results.

[2444] Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups. Session Type: Poster

[2445] High Incidence of Non-Neutropenic Infections Induced by Rituximab Plus Chemotherapy and Associated with Hypogammaglobulinemia: A Frequently Unrecognized and Easily Treatable Complication.

[2446] High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

[2447] Diffuse B-Large Cell Lymphomas (DBLCL) with Hepatitis-C Virus (HCV) Infection: Clinical Outcome and Preliminary Results of a Pilot Study Combining R-CHOP with Antiviral Therapy.

[2448] A Phase I Study of 90Y-Ibritumomab-Tiuxetan (90Y-It) in Children with Recurrent/Refractory CD20 Positive Lymphoma: A Cog Phase I Consortium Study.

[2449] Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).

[2450] Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin®; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin's Lymphoma (NHL).

[2451] Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.

[2452] Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

[2453] Consolidation of Chemotherapy Response in Mantle Cell Lymphoma (MCL) Patients with 90Y-Ibritumomab Tiuxetan (90Y-Zevalin) Radioimmunotherapy (RIT).

[2454] Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – First Interim Results of a Prospective Randomised Phase II Study. Session Type: Poster

[2455] Rituximab Retreatment in B-Cell Non-Hodgkins Lymphoma Patients.

[2456] Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.

[2457] Re-Treatment with Rituximab Plus Chemotherapy in Patients with Diffuse Large-B Cell Lymphoma (DLBCL): A Spanish Multicenter Study.

T-Cell and Hodgkin Lymphoma: Chemotherapy, excluding Pre-Clinical Models

[2667] Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin's Disease. 

[2668] Mortality during Treatment of Patients with Advanced Hodgkin's Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG). 

[2669] Computed Tomography (CT) Scan Response Stability and Gallium Scan Evaluation as On-Treatment Prognostic Parameters To Tailor Treatment Intensity of Newly Diagnosed Hodgkin's Lymphoma (HL). A Prospective Phase II Study. 

[2670] A Comparison of Outcome and Second Malignancies in Adolescents and Adult Patients with Hodgkin´s Lymphoma (HL). Results from the German Hodgkin Study Group. 

[2671] The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin's Lymphoma. 

[2672] Response Adapted Therapy: Using FDG-PET after Chemotherapy in Order To Restrict Indication for Radiotherapy in Children and Adolescents with Early Stages of Hodgkin's Lymphoma (HL). 

[2673] Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin's Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). 

[2674] Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin's Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG). 

[2675] CEBOPP/VIML Followed by Radiotherapy for Intermediate- and Advanced-Stage Hodgkin's Disease: A Long-Term Analysis. 

[2676] Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma Patients. 

[2677] Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins's Lymphoma: Long Term Follow-Up. 

[2678] Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity. 

[2679] Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

[2680] A Prospective Study of Combined m-BACOD Chemotherapy and Radiotherapy for Aggressive Nasal NK/T-Cell Lymphoma.

[2681] Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. 

[2682] Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institue Experience in Korea. 

[2683] Phase I/II Study of Oral FodosineTM, a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients. 

[2684] Infusional Adriamycin Based Chemotherapy Significantly Improves the Survival of Human T-Cell Lymphotropic Virus-I Induced Acute Type Adult T-Cell Leukemia Lymphoma. 

[2685] Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI. 

[2686] Rituximab in Combination with CHOP Regimen in Angioimmunoblastic T-Cell Lymphoma (AITL). Preliminary Results in 9 Patients Treated in a Single Institution.

Transplantation Regimen Toxicities and Engraftment II

[2730] MTHFR-A1298C Polymorphism Is Associated with Veno-Occlusive Disease (VOD) and Liver Toxicity after Busulfan/Cyclophosphamide Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). 

[2731] Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting. 

[2732] Increased Incidence of Metabolic Syndrome after Hematopoietic Stem Cell Transplantation. 

[2733] The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin. 

[2734] Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT). 

[2735] Successful Engraftment of Autologous CD34+ Stem Cells after High-Dose Therapy and Fixed Dose (6 mg) Pegfilgrastim. 

[2736] Autologous Bone Marrow Transplant after Failed Peripheral Blood Stem Cell Mobilization Does Not Adversely Affect Engraftment or Transplant Related Toxicity. 

[2737] High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting. 

[2738] Pre-Autologous Stem Cell Transplantation (ASCT) Treatment with Rituximab Does Not Impair Stem Cell Harvest and Engraftment in Untreated Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis. 

[2739] The Role of Alemtuzumab Compared to Antitymocyte Globulin in Non-Myeloablative Stem Cell Transplantation; Especially for the Prevention of GVHD and Immune Recovery. 

[2740] Permanent Alopecia in Children Following Busulfan Based Conditioning Is Associated with Glutathione M1 Null Genotype. 

[2741] Secondary Malignancies after Hematopoietic Stem Cell Transplantation in Patients Treated with Total Body Irradiation. 

[2742] Intravenous (i.v.) Busulfan (Bu) Plus Melphalan (Mel) Is a Well-Tolerated Preparative Regimen for Stem Cell Transplantation (SCT) in Patients (pts) with Advanced Lymphoid Malignancies. 

[2743] Hemophagocytic Syndrome (HPS) Post Reduced Intensity Cord Blood Transplantation (RI-CBT) in Adult Patients with Hematological Diseases. 

[2744] Allogeneic Blood Stem Cell Transplantation in Patients with Hematologic Diseases after Conditioning with Treosulfan and Fludarabine. 

[2745] Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse. 

[2746] Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders. 

B-Cell Lymphoma: Clinical Chemotherapy Trials

[13] Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). 

[14] Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma. Results of a Prospective Randomized HOVON Trial. 

[15] No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study. Session Type: 

[16] Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin's Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups. 

[17] Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin's Lymphoma (NHL): A Phase 2 Study. 

[18] Revised Response Criteria for Malignant Lymphomas. From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma

Clinical Results: Allogeneic Matched Related Donor Transplantation –Non-Myeloablative Approaches

[44] Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Session Type: 

[45] Updated Analysis of Hematopoietic Stem Cell Transplantations after Reduced Intensity Conditioning Regimen (RIC HSCT) for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry. 

[47] Allogeneic Hematopoietic Stem-Cell Transplantation in AML and MDS Using Myeloablative Versus Reduced Intensity Conditioning: The Role of Dose-Intensity. 

[48] Autologous Stem Cell (AUTO) vs. Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

Experimental Transplantation: T-Cell Recovery and Immunotherapy

[61] A Vaccination Regimen Incorporating the Synergistic Combination of CpG-Containing Oligodeoxynucleotides and IL-2 Can Elicit CD8+ T Cell Responses That Effect Anti-Tumor Immunity from T Cell Repertoires Undergoing Reconstitution by Homeostatic Peripheral Expansion after BMT. 

[62] In Vivo Demonstration of Donor Idiotype Specific T Cells That Kill Primary CLL Cells Post Allogeneic Transplant.

[63] Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. 

[64] Enhanced Immune Reconstitution and Function by CD4+CD25+ Regulatory T Cells Following Allogeneic Hematopoietic Cell Transplantation. 

[65] FcRγ-Dependent Facilitating Cells Are Direct Inducers of Regulatory T Cells. 

[66] Contrasting Effects of Post-Transplant Lymphopenia on Proliferation and Degranulation in Antigen-Specific CD8 Memory T Cells. 

Acute and Chronic GVHD

[139] Risk Factors and Outcome of Chronic GVHD: Analysis of 5,660 Patients Undergoing Unrelated Bone Marrow Transplantation through the Japan Marrow Donor Program. 

[140] T-Cell Depleted PBSCT Mitigates Acute GVHD, but Preserves Protective Chronic GVHD. Long Term Follow up of 138 Patients. 

[141] Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone. 

[142] Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD). 

[143] Mesenchymal Stem Cells for Treatment of Severe Acute and Extensive Chronic Graft-Versus-Host Disease. 

[144] NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation. 

BCL-6 and Gene Expression Profiling in NHL

[157] BCL6 Attenuates DNA Damage Sensing in Normal and Malignant B-Cells by Directly Repressing ATR. 

[158] BCL6 Is Regulated by p53 through a Response Element Frequently Disrupted in B-Cell Non-Hodgkin's Lymphoma. 

[159] Gene Expression Profile Associated with Survival in Patients with Diffuse Large B-Cell Lymphoma Treated by Chemotherapy and Rituximab. 

[160] Distinctive Patterns of BCL6 Molecular Alterations in Different Subsets of Diffuse Large B-Cell Lymphoma and Their Functional Consequences. 

[161] Significant Differences in the IGVH and BCL6 Mutation Status in Aggressive B-Cell Lymphomas with and without MYC Breakpoints. 

[162] Analysis of IgVH, BCL-6, PIM, RHO/TTF and PAX5 Mutational Status in Splenic and Nodal Marginal Zone B Cell Lymphoma Suggests a Particular B Cell Origin

Clinical Results: Allogeneic Matched Related Donor Transplantation – Myeloablative Approaches

[171] Should Stem Cell Transplantation (SCT) Be Recommended for Any Child with AML in 1st CR? 

[172] Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. 

Lymphoma: Novel Chemotherapy and Pediatric Clinical Trials

[229] Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

[230] Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin's Lymphoma (NHL). 

[231] Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide. 

[232] Secondary Neoplasms Subsequent to Berlin-Frankfurt-Muenster (BFM) Therapy of Non-Hodgkin Lymphoma of Childhood: Significantly Higher Risk for Patients with Lymphoblastic Lymphoma Compared to Other NHL-Subtypes. 

[233] CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient´s Outcome Differ According to the Subtype. 

Clinical Results: Autologous Transplantation

[2918] Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma. 

[2924] Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications. 

[2925] Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT). 

[2929] A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma. 

[2933] Tymic Output after Autologous Bone Marrow Transplantation (ASCT) HIV-Related Lymphoma.

Lymphoma: Chemotherapy, excluding Pre-Clinical Models

[3326] Treatment of Childhood T Cell Lymphoblastic Lymphoma (TLL), Results of the SFOP LMT96.

[3327] Time to Failure and CD3-Expression Are Strong Prognostic Factors in Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence.

[3328] A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.

[3329] Delivery and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Older Patients.

[3330] Unexpectedly High Incidence of Interstitial Pneumonia in Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with Rituximab-CHOP-14 Supported with Pegfilgrastim.

[3331] MCP (Mitoxantrone/Chlorambucil/Prednisolone) Chemotherapy Impairs the Subsequent Collection of Stem Cells in Comparison to CHOP Induction in Patients with Indolent Lymphomas – Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

[3332] Successful Treatment of Tumor Lysis Syndrome (TLS) with Low Doses of Rasburicase in Patients with Impaired Renal Function (IRF).

[3333] Incidence and Risk Factors for Central Nervous System Manifestation in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma.

[3334] Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin's Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

[3335] Treatment Stratification According to Early Response to Mega-CHOP, Based on CT and Gallium 67 Scan (G67S) with or without IFE Salvage Therapy Followed by Peripheral Autologous Stem Cell Transplant (PBSCT) in Patient with Poor Prognosis Aggressive Lymphoma. A Preliminary Report from a Prospective GEL/TAMO Trial.

[3336] An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

[3337] Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.

[3338] Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

[3339] Splenectomy for Splenic Marginal B-Cell Lymphoma.

[3340] Systematic Review of 18F-Fluorodeoxyglucose Positron Emission Tomography for Post-Treatment Evaluation of Malignant Lymphoma.

[3341] Phase I Study of Noscapine for Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy.

[3342] Primary CNS Lymphoma Treated with HD-Methotrexate, HD-Busulfan/Thiotepa, Autologous Stem Cell Transplantation and Response-Adapted Whole-Brain Radiotherapy: Results of the Multicenter OSHO-53 Phase II - Study.

[3343] International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models III

[3344] Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma.

[3345] CHOP Chemotherapy Plus Campath-1H (CHOP-C) as First Line Treatment in Patients with Peripheral T-Cell Lymphoma (PTCL).

[3346] Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.

[3347] Durable Remission with Decreased HTLV-I Proviral Load after Reduced-Intensity Stem Cell Transplantation (RIST) in Patients with Adult T-Cell Leukemia/Lymphoma (ATL).

[3348] A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies.

[3349] Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.

[3350] Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma.

[3351] Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.

[3352] CD4 T-Helper Responses to the ALK Protein in Patients with ALK-Positive ALCL.

[3353] Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

[3354] HuMax-CD4 (Zanolimumab), a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphoma of Non-Cutaneous Type.

[3355] Primary Gastric T-Cell Lymphoma: Clinicopathologic Features and Treatment Outcome.

[3356] SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Transplantation Regimen Toxicities and Engraftment III

[3658] Reduced Intensity Conditioning Regimen for Unrelated Cord Blood Transplantation in Adults. A Multicentric Phase I-II Trial.

[3659] Non-Myeloablative Allogeneic Transplantation (NMT) with T-Cell Replete Graft for Relapsed Chemosensitive Follicular Lymphoma (FL): Donor Lymphocyte Infusion (DLI) To Convert Stable Mixed Chimerism to Full Donor Chimerism Is Not Necessary in the Absence of Disease Progression.

[3660] Results of T Cell Depleted (TCD) Myeloablative Hematopoietic Stem Cell Transplants (HSCT) in Patients with Hematologic Malignancies ≥ 55 yrs of Age.

[3661] Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

[3662] Allograft T Cell Content Influences Early Engraftment after Reduced-Intensity Stem Cell Transplantation (RIST).

[3663] Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT.

[3664] Efficacy of Performing a Second Non-Myeloablative Allogenic Stem Cell Transplant.

[3665] Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

[3666] Allogeneic Myelo-Ablative Stem Cell Transplant (SCT) as Salvage Therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.

[3667] Very High Hospital Admission Rate after Outpatient Non-Myeloablative Allogeneic Stem Cell Transplant Using Fludarabine and Low Dose TBI.

[3668] Minimal HLA Disparity and KIR Ligand Compatibility in Host Versus Graft Direction May Facilitate Donor Engraftment Following In Vivo and Ex Vivo T Cell Depleted (TCD) Nonmyeloablative Haploidentical Stem Cell Transplantation for Hematologic Malignancies. [

[3669] Kinetics of Early Donor Chimerism after Nonmyeloablative Haematopoietic Stem Cell Transplantation Monitored with High-Resolution Real Time Quantitative PCR.

[3670] Allogeneic Stem Cell Transplantation (SCT) with Reduced-Intensity Conditioning (RIC) in Children with Malignancies: A Retrospective Study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

[3671] Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) for Hematologic Malignancies (HM) Using Pentostatin/Low-Dose Total Body Irradiation (TBI).

[3672] Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (SCT) with Pre-Transplant Targeted Immune Depletion Results in Rapid Full Donor Engraftment in Pediatric Patients with Malignancy.

[3673] Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

[3674] Improved Post-Transplant Outcomes in Hematologic Malignancy Patients Undergoing Non-Myeloablative Hematopoietic Stem Cell Transplant (NMHSCT) Using a 400 cGy Total Body Irradiation (TBI) Dose with Fludarabine.

[3675] Lymphoid Chimerism (LC) Kinetic after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).

Lymphoma: Pre-Clinical – Immunotherapy

[343] Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas.

[344] CpG in the Immunotherapy of B-Cell Lymphoma.

[345] IL-21 Improves Rituximab-Mediated B Cell Depletion.

[346] Preclinical Safety and Efficacy of Two Novel Immunotoxins Consisting of Ranpirnase (Rap) Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody in Human Non-Hodgkin's Lymphoma Xenografts.

[347] Rituximab Variants with Re-Engineered Fc with Higher Affinity to Activating FcγR Eliminate the Functional Difference between FcγR Genotypes.

[348] Anti-CD20 Monoclonal Antibody (mAb) with Enhanced Affinity for CD16 Activates NK Cells at Lower Concentrations and More Effectively Than Rituximab ®

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models I

[349] Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.

[350] Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin's Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

[351] Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis.

[352] An Update of a Phase II Trial of CHOP Followed by Tositumomab/ Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.

[353] Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin's Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

[354] Low Dose Radiation Induces a Highly Effective p53 Response and Rapid Tumor Regression in Follicular Lymphoma.

Transplantation Regimen Toxicities and Engraftment I

[397] 131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

[398] Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.

[399] Defibrotide (DF) for the Treatment of Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Analysis of Response and Survival According to Degree and Type of MOF.

[400] Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group.

[401] Reduced Intensity Allogeneic Transplantation for Non-Hodgkin's Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen.

[402] Results of Haematopoietic Stem Cell Transplantation (HSCT) for Hurler's Syndrome: European Experience 1994-2004.

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models II

[487] A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.

[488] High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

[489] Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL).

[490] Phase II Study of Bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248.

[491] Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results.

[492] Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Reduced Intensity Transplantation: Clinical Outcome

[655] Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

[656] Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma.

[657] Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin's Lymphoma Relapsing Post-Autologous Transplantation.

[658] Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

[659] Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).

[660] Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.

Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

[675] Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.

[676] Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

[677] Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

[678] The Role of High Dose Therapy and Stem Cell Rescue in the Management of T-Cell Malignant Lymphomas (TCL): A BSBMT and ABMTRR Study.

[679] The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma.

[680] Primary CNS Lymphoma – High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy – Results of a Multicenter Phase II Study.

[681] New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

[682] Can Elimination of Total Body Irradiation (TBI) in Conditioning Regimens for Autologous Stem Cell Transplantation (SCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma Decrease the Risk of Secondary AML/MDS(sAML/MDS)? A Retrospective Case-Control Study at the University of Nebraska Medical Center.

Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models III

[771] Use of Dendritic Cells and GM-CSF Adjuvant Are Associated with Anti-Idiotype Cellular Immune Response Following Idiotype Vaccination in Follicular Lymphoma Patients.

[772] Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId® (Id/KLH) Vaccine Following Rituximab.

[773] The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.

[774] Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

[775] Complement-Induced Cell Death by Rituximab Depends on CD20-Expression Level and Acts Complementary to Antibody-Dependent Cell-Mediated Cytotoxicity.

[776] Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab.

[777] Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype Are Associated with Better Clinical Outcome Following Idiotype Vaccination in Follicular Lymphoma Patients Regardless of Their Response to Induction Chemotherapy.

[778] A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.

Transplantation Regimen Toxicities and Engraftment II

[835] HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.

[836] Platelet Engraftment (PE) in AML Patients Receiving HLA Matched Sibling Donor Allogeneic Bone Marrow Transplant (ABMT) Correlates with Inhibitory HLA Ligand Groups for Killer Immunoglobulin-Like Receptors (KIRs).

[837] Severe Mucositis Adversely Affects Survival after Autologous Stem Cell Transplantation (ABMT) for Lymphoid Malignancies.

[838] Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

[839] Melphalan 200mg/m2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

[840] Comparison of Different TBI Based Conditioning Regimen in Pediatric Haematological Malignancies: A Retrospective Study of 702 Patients from French Registry.

[841] Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

[842] Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.